eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | pancreatitis |
| Comorbidity | C0011860|type 2 diabetes |
| Sentences | 22 |
| PubMedID- 24674587 | Prophylactic effects of the glucagon-like peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity. |
| PubMedID- 23269874 | In recent years, postmarketing safety surveillance has raised concerns about the risk of pancreatitis in patients with type 2 diabetes who receive antidiabetic therapies. |
| PubMedID- 23300896 | Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a japanese hospital database. |
| PubMedID- 24651798 | That study used a large insurance database of more than 1 million people, and reported increased odds of hospitalizations for acute pancreatitis in patients with type 2 diabetes 64 years of age or younger that were prescribed either exenatide or saxagliptin. |
| PubMedID- 19894028 | In one such study, the incidence of pancreatitis was increased in patients with type 2 diabetes treated with the glp-1 analogue liraglutide [10]. |
| PubMedID- 20371755 | Objective: to review the possible association between glucagon-like peptide-1 (glp-1) agonist use and pancreatitis in patients with type 2 diabetes mellitus. |
| PubMedID- 20412332 | The incidence of pancreatitis is increased in patients with type 2 diabetes (t2dm), and cases of pancreatitis have been reported in patients using most categories of antihyperglycemic medications. |
| PubMedID- 26269615 | Glucagon-like peptide-1 (glp-1) receptor agonist therapy has been implicated as a possible risk factor for acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 24736555 | Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. |
| PubMedID- 24859164 | Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. |
| PubMedID- 24764569 | As incretin based drugs are typically second to third line drugs2 and the risk of acute pancreatitis increases with type 2 diabetes and possibly with duration of disease,404142 it is imperative that they are compared with drugs used at the same or a similar stage of diabetes, otherwise this would introduce a time lag bias.43 it is for this reason that our primary comparator group consisted of sulfonylurea users, which we believe is the clinically most appropriate comparator. |
| PubMedID- 26512613 | To investigate the effects of dipeptidyl peptidase-4 (dpp-4) inhibitors on the risk of acute pancreatitis in patients with type 2 diabetes.this nationwide population-based cohort study used the diabetes patients dataset of taiwan's national health research insurance research database. |
| PubMedID- 21525466 | Up-to-date observational reports and clinical study data revealed that 44 cases of acute pancreatitis occurred in patients with type 2 diabetes while taking exenatide (8 cases during clinical development and 36 postmarketing reports), 4 cases of pancreatitis in liraglutide-treated patients (in clinical trials), and none during therapy with albiglutide or taspoglutide (51). |
| PubMedID- 20833867 | The results of this study confirm the excess risk of acute pancreatitis associated with type 2 diabetes previously reported in other observational studies (2,4,5). |
| PubMedID- 21324812 | Conclusions: although incretin-based therapy effectively treats type 2 diabetes mellitus, emerging reports of acute pancreatitis in patients receiving sitagliptin and exenatide have prompted the us food and drug administration to issue an alert on these drugs. |
| PubMedID- 21577242 | Objectives: the objective of this study was to assess the risk of acute pancreatitis among patients with type 2 diabetes mellitus (dm) and identify the roles of co-morbidities and anti-diabetic drugs. |
| PubMedID- 26059826 | Clinical and nonclinical studies have implicated glucagon-like peptide-1 (glp-1) receptor agonist therapy as a risk factor for acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 20682680 | (11) recently reported a lower risk of acute pancreatitis in patients with type 2 diabetes (adjusted hr of 1.49). |
| PubMedID- 24622714 | Larger studies are needed to clarify whether age or type of incretin therapy could affect the risk of acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 20103558 | Notably, analysis of pancreatitis in subjects with type 2 diabetes suggests that their risk is increased threefold over nondiabetic subjects (21). |
| PubMedID- 23440284 | Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. |
| PubMedID- 24818338 | Treatment with dpp-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes. |
Page: 1